Silver Book Fact

Slowing the progression of Parkinson’s disease by just 10% would save $327 million (in direct and indirect costs) to the U.S. annually.

Kurlan, R., Clark S., Shoulson Ira, et al. Economic Impact of Protective Therapy for Early Parkinsonâ??s Disease. Ann Neurol. 1988; 24(1): 153

Reference

Title
Economic Impact of Protective Therapy for Early Parkinsonâ??s Disease
Publication
Ann Neurol
Publication Date
1988
Authors
Kurlan, R., Clark S., Shoulson Ira, et al.
Volume & Issue
Volume 24, Issue 1
Pages
153

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Donepezil, a new Alzheimer’s medication, increased prescription costs to $1,000 per patient, however the overall health care costs decreased from $11,947 to $8,056.  
  • Medicines Allow Patients to Remain Independent Longer: New Alzheimer’s medicine delays need for costly home care  
  • In one study, Alzheimer’s patients who took donepezil had an increase in their prescription costs of $1,000 per patient, but saw reduced total medical costs of about 1/3–from $11,947 to…  
  • Galantamine, a cholinesterase inhibitor, delays Alzheimer’s patients’ need for full-time care, with overall cost savings estimated between $323 and $4,256 per patient.  
  • Medicaid Costs, Slowed Progression